United States Aquaculture vaccines market is growing with a CAGR of 9% - Driven by rising fish farming, disease outbreaks, demand for antibiotic-free seafood, and advances in vaccine tech. | DataM Intelligence

The global Aquaculture vaccines market is valued at about USD 400-500 million and is set to more than double by 2030-2034, growing at a strong 9% CAGR.

The market is growing due to rising fish farming, disease outbreaks, demand for antibiotic-free seafood, and advances in vaccine tech.

Download Free sample report:-https://www.datamintelligence.com/download-sample/aquaculture-vaccines-market?pratik

Recent Industry Development in U.S market:

✅ The U.S. aquaculture vaccines market generated USD 62.4 million in 2023, and is projected to reach USD 109.5 million by 2030, with a CAGR of 8.4% from 2024 to 2030.

✅ Inactivated (killed) vaccines represented the largest vaccine type segment by revenue in the U.S. in 2023.

✅ "Other vaccines" (beyond live or inactivated) are expected to register the fastest growth in the forecast period (2024-2030).

✅ There is a clear shift to sustainable aquaculture, with vaccine adoption driven by efforts to reduce antibiotic usage in fish farming.

✅ Regulatory and institutional support: Federal agencies (USDA, FDA) plus academic collaborations (Cornell, Auburn) are backing vaccine R&D and adoption in U.S. aquaculture.

Recent Industry Development in Japan market:

✅ Japan's aquaculture vaccines market share in Asia-Pacific is about 5.2% (USD 28.6 million) in 2025, growing at ~8.0% CAGR.

✅ Japan is among the leading adopters: its live vaccine sub-market is estimated at USD 27.8 million.

✅ In viral-infection vaccines ( for viral diseases in fish), Japan's market is forecast to be USD 34.1 million, with a CAGR of 8.3%.

✅ Government policy support: Japan's fisheries policy explicitly calls for "fish disease countermeasures" through development and diffusion of vaccines. jfa.maff.go.jp

✅ R&D and regulatory ecosystem: Japan has high R&D capacity, and there are domestic players (e.g., Nisseiken) active in vaccine development.

Key Investment

➠Merck Animal Health / MSD (U.S.): Completed acquisition of Elanco's aqua business in mid-2024 - deal announced at USD 1.3 billion (cash), strengthening Merck's vaccine & therapeutics portfolio for aquaculture.

➠Elanco (U.S., divestiture): Sold its aqua business to Merck (deal value USD 1.3 billion) - a major sector consolidation that signalled strong strategic interest and value in commercial fish-vaccine assets.

➠Zoetis (U.S.): Large ongoing R&D investment supporting animal-health vaccines (Research & Development expense ~USD 686 million in 2024) and targeted aquaculture analytics/vaccine efforts-illustrates big pharma's funding of vaccine innovation + digital disease-prediction tools for aquaculture.

➠Indian Immunologicals Limited (India): Strategic commercialisation pact with ICAR-CIBA (Aug 29, 2024) to produce CIBA's finfish vaccine "Nodavac-R"; IIL is also investing in expanded vaccine manufacturing capacity (announced investment plan ~Rs 700 crore for new animal-vaccine facilities). This represents notable public-private investment in regional aquaculture vaccine capacity.

➠Vaxxinova / regional specialists (Netherlands/Brazil): Expanding aquaculture business unit and global product roll-outs (new aquaculture division / commercial focus announced), backed by corporate R&D and regional market investments - showing growth of specialist vaccine companies beyond large incumbents.

Benefits of AI for the Aquaculture Vaccine Market

➠ Enhanced disease monitoring with AI-powered early detection of pathogens, enabling timely intervention to reduce outbreaks.

➠ Optimization of vaccine development through AI-driven genetic analysis and pathogen identification to create targeted and effective vaccines.

➠ Precision vaccination schedules tailored by AI algorithms to improve immune responses and reduce vaccine waste.

➠ Automation of fish health and behavior monitoring to identify stress or illness, supporting better vaccine efficacy assessment.

➠ Improved biosecurity management by AI systems that track environmental conditions and pathogen risks in real time.

➠ AI-driven data analytics to optimize vaccine delivery methods (injection, oral, immersion) for different species and farm conditions.

➠ Cost reduction and operational efficiency by predicting disease outbreaks and reducing unnecessary vaccination.

"Secure your 30% year-end discount - get this report before the offer expires."
:https://www.datamintelligence.com/buy-now-page?report=aquaculture-vaccines-market?pratik ((Purchase 2 or more Repots and get 50% Discount)

Segmentation Analysis :

➠ By Type:
Attenuated live vaccines, inactivated vaccines, subunit vaccines, DNA vaccines, and recombinant vaccines form the core portfolio, with inactivated and recombinant vaccines gaining stronger adoption due to higher safety, stability, and regulatory acceptance. DNA and subunit vaccines are emerging as advanced options offering targeted immune responses.

➠ By Route of Administration:
Injected vaccines dominate usage because they provide high efficacy and long-term protection, especially in high-value species like salmon and trout. Oral and immersion routes are increasingly preferred for mass vaccination, offering easier handling and reduced stress on fish stocks. Other delivery methods serve niche applications.

➠ By Application:
Bacterial infection vaccines lead the market owing to the high prevalence of diseases like vibriosis and furunculosis in aquaculture farms. Viral infection vaccines are expanding steadily due to increasing outbreaks and rising mortality risks. Parasitic infection vaccines remain in early development but show long-term growth potential.

➠ By Species Type:
Salmon and trout account for the largest share, driven by large-scale commercial farming in major producing countries. Tilapia follows with rising vaccine adoption to reduce losses in intensive farming systems. Seabass and seabream represent growing segments with increasing regional aquaculture production.

➠ By End-user:
Veterinary hospitals and clinics remain the primary users, offering professional administration and disease management support. Other end users-including commercial farms and aquaculture research centers-are expanding their vaccine usage as biosecurity awareness increases.

Regional Insights:

➠North America: Largest market - 38% of global aquaculture-vaccine sales in 2024. Growth is driven by high aquaculture production value chains, strong private-sector adoption of biosecurity measures, advanced veterinary R&D and established distribution channels.

➠Asia-Pacific: Fastest-growing region - APAC share 20% (rising fastest) with an estimated CAGR 7.4% driven by rapid expansion of aquaculture in China, India, Southeast Asia and modernization programs (higher vaccine adoption, disease control initiatives and rising seafood demand).

➠Europe: Mature, stable market with moderate growth - strong focus on regulatory compliance, sustainability and reduced antibiotic use; growth supported by established players, targeted vaccines for salmonid industries (Norway/UK) and investments in cold-chain and injection/immersion vaccination technologies.

Growth drivers:

Rising demand for aquaculture products globally.

Increasing prevalence of diseases due to pollution and intensive farming.

Government support and regulatory pressure for antibiotic-free aquaculture.

Advancements in vaccine technology, including recombinant and inactivated vaccines.

Expansion of fish farming in developing countries and emerging markets.

Consumer demand for sustainable and safe seafood.

Innovations in vaccine delivery such as oral and immersion methods.

Digital monitoring and health management technologies.

Increasing production of high-value species like salmon.

Global trade and climate change increasing pathogen transmission risks.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/aquaculture-vaccines-market?pratik

Key players:

Merck & Co., Inc., convex, Hipra, Zoetis LLC, Phibro Animal Health Corporation, Elanco, KBNP, INC., Kyoto Biken Laboratories, Inc., Veterquimica S.A., Virbac S.A.

Key highlights:

➠ Zoetis LLC
Leading innovator known for advanced DNA and recombinant vaccines for salmonids and high-value species. Its strong distribution network and continuous investments in precision aquaculture health solutions boost its share in the global market.

➠ HIPRA
A major European specialist recognized for customized autogenous vaccines and cutting-edge biotechnology vaccine platforms. HIPRA's expanding vaccine production facilities and focus on antimicrobial reduction in aquaculture enhance its presence in Asia-Pacific and Latin America.

➠ Phibro Animal Health Corporation
Key market participant delivering cost-effective and broad-spectrum aquaculture vaccines aimed at tilapia, trout, and warm-water species. Strong penetration in emerging markets with a focus on disease prevention programs and farmer training initiatives.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?pratik
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insightsthrough pricing analysis, market share breakdowns, and competitive intelligence. Thecompany specializes in strategic reports that guide businesses in high-growth sectors suchas nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,LinkedIn and Facebook.

This release was published on openPR.